Bryn Mawr Capital Management LLC Acquires 1,642 Shares of Danaher Corporation (NYSE:DHR)

Bryn Mawr Capital Management LLC raised its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 2.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 74,956 shares of the conglomerate's stock after acquiring an additional 1,642 shares during the period. Danaher makes up 0.9% of Bryn Mawr Capital Management LLC's investment portfolio, making the stock its 24th biggest holding. Bryn Mawr Capital Management LLC's holdings in Danaher were worth $15,366,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Danaher by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 59,750,122 shares of the conglomerate's stock worth $13,715,641,000 after purchasing an additional 315,912 shares during the period. Geode Capital Management LLC grew its holdings in shares of Danaher by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate's stock worth $3,056,996,000 after acquiring an additional 315,446 shares during the period. Norges Bank acquired a new stake in shares of Danaher in the 4th quarter worth approximately $2,130,740,000. Bank of New York Mellon Corp lifted its stake in Danaher by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after buying an additional 194,466 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in Danaher by 14.3% in the 4th quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate's stock valued at $1,821,477,000 after buying an additional 992,594 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Down 2.5%

Shares of Danaher stock traded down $4.81 on Friday, hitting $189.98. 4,162,691 shares of the company traded hands, compared to its average volume of 4,183,200. The company has a 50-day moving average price of $196.12 and a 200 day moving average price of $205.48. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $281.70. The company has a market cap of $135.96 billion, a PE ratio of 36.89, a PEG ratio of 2.71 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. The firm had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. Danaher had a net margin of 15.81% and a return on equity of 10.80%. Sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.67%. Danaher's payout ratio is presently 24.85%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on DHR shares. Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Guggenheim reaffirmed a "buy" rating and issued a $250.00 target price on shares of Danaher in a research report on Wednesday, April 23rd. Bank of America cut their price objective on Danaher from $265.00 to $230.00 in a research report on Monday, April 14th. Argus lowered their target price on Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. Finally, The Goldman Sachs Group lowered their target price on Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, Danaher currently has an average rating of "Moderate Buy" and a consensus target price of $248.48.

Insider Activity

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the transaction, the executive vice president owned 15,179 shares in the company, valued at $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman directly owned 3,105,808 shares in the company, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.